抗结核药物治疗方案非临床评价中的中空纤维系统模型 - Suppr

Suppr

超能文献

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

作者信息

Chilukuri Dakshina, McMaster Owen, Bergman Kimberly, Colangelo Philip, Snow Kerry, Toerner Joseph G

机构信息

Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.

Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

出版信息

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

DOI:10.1093/cid/civ460

PMID:26224770

Abstract

摘要

相似文献

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484.

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.

Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.

Antimicrob Agents Chemother. 2005 Oct;49(10):4335-8. doi: 10.1128/AAC.49.10.4335-4338.2005.

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427.

Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.

FEMS Microbiol Lett. 2006 Aug;261(2):181-6. doi: 10.1111/j.1574-6968.2006.00350.x.

Nonclinical models for antituberculosis drug development: a landscape analysis.

J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183.

Drug resistance in tuberculosis.

J Chemother. 1990 Jun;2(3):147-51. doi: 10.1080/1120009x.1990.11739007.

Trench warfare in a battle with TB.

Science. 2008 Jul 18;321(5887):362-4. doi: 10.1126/science.321.5887.362.

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.

引用本文的文献

Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.

Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.

Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6.

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.

J Antimicrob Chemother. 2023 Apr 3;78(4):953-964. doi: 10.1093/jac/dkad029.

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of , methodologies and human studies.

Front Pharmacol. 2022 Dec 9;13:1063453. doi: 10.3389/fphar.2022.1063453. eCollection 2022.

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating .

Front Pharmacol. 2021 Jan 19;11:616294. doi: 10.3389/fphar.2020.616294. eCollection 2020.

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.

Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01207-20.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02232-17. Print 2018 Feb.

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.

The Role of Public-Private Partnerships in Catalyzing the Critical Path.

Clin Transl Sci. 2017 Nov;10(6):431-442. doi: 10.1111/cts.12488. Epub 2017 Aug 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

作者信息

Chilukuri Dakshina, McMaster Owen, Bergman Kimberly, Colangelo Philip, Snow Kerry, Toerner Joseph G

机构信息

Center for Drug Evaluation and Research, Office of Clinical Pharmacology, Office of Translational Sciences.

Office of New Drugs, US Food and Drug Administration, Silver Spring, Maryland.

出版信息

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

DOI:10.1093/cid/civ460

PMID:26224770

Abstract

摘要

相似文献

The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484.

Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.

Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.

Antimicrob Agents Chemother. 2005 Oct;49(10):4335-8. doi: 10.1128/AAC.49.10.4335-4338.2005.

Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S25-31. doi: 10.1093/cid/civ427.

Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.

FEMS Microbiol Lett. 2006 Aug;261(2):181-6. doi: 10.1111/j.1574-6968.2006.00350.x.

Nonclinical models for antituberculosis drug development: a landscape analysis.

J Infect Dis. 2015 Jun 15;211 Suppl 3:S83-95. doi: 10.1093/infdis/jiv183.

Drug resistance in tuberculosis.

J Chemother. 1990 Jun;2(3):147-51. doi: 10.1080/1120009x.1990.11739007.

Trench warfare in a battle with TB.

Science. 2008 Jul 18;321(5887):362-4. doi: 10.1126/science.321.5887.362.

Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.

引用本文的文献

Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant in the hollow fiber system model.

Antimicrob Agents Chemother. 2024 Feb 7;68(2):e0108023. doi: 10.1128/aac.01080-23. Epub 2023 Dec 22.

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.

Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6.

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.

J Antimicrob Chemother. 2023 Apr 3;78(4):953-964. doi: 10.1093/jac/dkad029.

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of , methodologies and human studies.

Front Pharmacol. 2022 Dec 9;13:1063453. doi: 10.3389/fphar.2022.1063453. eCollection 2022.

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating .

Front Pharmacol. 2021 Jan 19;11:616294. doi: 10.3389/fphar.2020.616294. eCollection 2020.

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.

Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01207-20.

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S317-S326. doi: 10.1093/cid/ciy609.

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02232-17. Print 2018 Feb.

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.

Sci Adv. 2017 Aug 30;3(8):e1701102. doi: 10.1126/sciadv.1701102. eCollection 2017 Aug.

The Role of Public-Private Partnerships in Catalyzing the Critical Path.

Clin Transl Sci. 2017 Nov;10(6):431-442. doi: 10.1111/cts.12488. Epub 2017 Aug 3.